Format

Send to

Choose Destination
Nat Commun. 2016 Aug 22;7:12336. doi: 10.1038/ncomms12336.

Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma.

Author information

1
Department of Pediatrics, Children's Research Institute, Dallas, Texas 75390, USA.
2
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
3
Cancer Development and Treatment Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia.
4
Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Melbourne, Victoria 3010, Australia.
5
Life Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109-2216, USA.
6
Department of Dermatology, University of Michigan, Ann Arbor, Michigan 48109-2216, USA.
7
Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas Texas 75390, USA.

Abstract

New therapies are required for melanoma. Here, we report that multiple cardiac glycosides, including digitoxin and digoxin, are significantly more toxic to human melanoma cells than normal human cells. This reflects on-target inhibition of the ATP1A1 Na(+)/K(+) pump, which is highly expressed by melanoma. MEK inhibitor and/or BRAF inhibitor additively or synergistically combined with digitoxin to induce cell death, inhibiting growth of patient-derived melanomas in NSG mice and synergistically extending survival. MEK inhibitor and digitoxin do not induce cell death in human melanocytes or haematopoietic cells in NSG mice. In melanoma, MEK inhibitor reduces ERK phosphorylation, while digitoxin disrupts ion gradients, altering plasma membrane and mitochondrial membrane potentials. MEK inhibitor and digitoxin together cause intracellular acidification, mitochondrial calcium dysregulation and ATP depletion in melanoma cells but not in normal cells. The disruption of ion homoeostasis in cancer cells can thus synergize with targeted agents to promote tumour regression in vivo.

PMID:
27545456
PMCID:
PMC4996948
DOI:
10.1038/ncomms12336
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center